The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today approved the proposal of the Executive Board and Supervisory Board and resolved to pay a dividend of EUR 0.22 per share (previous year: EUR 0.17) for the 2025 fiscal year. As in previous years, the Annual General Meeting was held as an in-person event, right next to the Eckert & Ziegler SE headquarters in Berlin. In total, 55.37 % of the company’s share capital was represented. The Annual General Meeting endorsed the members of the Executive Board and the Supervisory Board of Eckert & Ziegler SE for the 2025 fiscal year and approved all items on the agenda by a large majority.
The dividend increase from EUR 0.17 to EUR 0.22 per share represents a 29% rise, underscoring the company's robust financial health and confidence in future growth. The detailed voting results of the Annual General Meeting and the CEO’s presentation are available on the Eckert & Ziegler SE website. This decision aligns with the company's strategy to reward shareholders while investing in its core business of isotope-related components for nuclear medicine and radiation therapy.
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. The approved dividend reflects the company's commitment to creating value for its shareholders while continuing to contribute to saving lives through its innovative medical solutions.
